These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397 [TBL] [Abstract][Full Text] [Related]
15. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Rutgeerts PJ; Fedorak RN; Hommes DW; Sturm A; Baumgart DC; Bressler B; Schreiber S; Mansfield JC; Williams M; Tang M; Visich J; Wei X; Keir M; Luca D; Danilenko D; Egen J; O'Byrne S Gut; 2013 Aug; 62(8):1122-30. PubMed ID: 22717454 [TBL] [Abstract][Full Text] [Related]
16. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Reinisch W; Panés J; Khurana S; Toth G; Hua F; Comer GM; Hinz M; Page K; O'Toole M; Moorehead TM; Zhu H; Sun Y; Cataldi F Gut; 2015 Jun; 64(6):894-900. PubMed ID: 25567115 [TBL] [Abstract][Full Text] [Related]
17. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE; Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857 [TBL] [Abstract][Full Text] [Related]
18. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231 [TBL] [Abstract][Full Text] [Related]